Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
Exhibitors at UBIFRANCE French Pavilion
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
IN-CELL-ART<br />
1 place Alexis Ricordeau<br />
44093 NANTES - FRANCE<br />
Phone: +33 2 40 71 67 17<br />
Email: info@incellart.com<br />
Web site: www.incellart.com<br />
IN CELL ART is a french biopharmaceutical company specializing in preclinical and<br />
pharmaceutical development of nanocarriers for macromolecular drugs. Its founder<br />
and research team, which includes a Nobel Prize Laure<strong>at</strong>e, have designed new classes<br />
of vectors th<strong>at</strong> are organized on a nanometric scale, which enables them to cross the<br />
cell barrier efficiently and safely. Products:<br />
• antibody production by genetic immuniz<strong>at</strong>ion. IN CELL ART technologies allows<br />
rapid and low cost production of antibodies with better specificity and affinity<br />
• DNA vaccine and siRNA therapeutics.<br />
INDICIA BIOTECHNOLOGY<br />
33 avenue de la Californie<br />
69600 OULLINS - FRANCE<br />
Phone: +33 4 72 39 14 92<br />
Fax: +33 4 72 39 16 01<br />
Email: infos@indicia.fr<br />
Web site: www.indicia.fr<br />
Contact: Stéphane LEGASTELOIS<br />
Indicia Biotechnology, specialist in immunotechnology and biochemistry, provides<br />
R&D and Manufacturing contracts to the biopharmaceutical and in vitro diagnostic<br />
industries to support their research, development of bioanalytical methods and<br />
safe production (under ISO 9001:2008, ISO13485, QSR and GMP intern<strong>at</strong>ional quality<br />
standards).<br />
We offer tailor-made solutions to measure biological targets (companion diag tests,<br />
methods to evalu<strong>at</strong>e immunogenicity, assays for biomarkers, immunomonitoring, QC<br />
methods…). Our technical services include immunoassays development and particles<br />
technologies (ELISA, Multiplex assays, l<strong>at</strong>eral flow, Singulex technology, a ntibodies<br />
development…).<br />
44
Change language